Abamune L is prescribed alongside other antiretroviral therapies to treat adults who are infected with HIV-1. Each pill contains the equivalent of 300 mg of Lamivudine IP and 600 mg of Abacavir. To effectively prevent the progression of HIV to AIDS, it is necessary to take at least one additional anti-HIV medication with Abamune L.
The suggested dosage of Abamune L for adults is one pill per day, in conjunction with other antiretroviral drugs. It can be consumed with or without food.
Patients with liver impairment should avoid taking Abamune L. Those with a history of hypersensitive reactions to Abacavir or any components of Abamune L should not use this medication. It is advised to refrain from taking any products containing Abacavir after experiencing a hypersensitive reaction.
The use of Abamune L has been linked to certain side effects, including migraine, rash, nausea, fatigue, vomiting, diarrhea, gastritis, abnormal dreams, vertigo, headache, fever, anxiety, depression, and insomnia.
In rare cases, there have been reports of fatal hypersensitive reactions to Abacavir, a key ingredient in Abamune L. Other side effects may occur as well. If you notice any changes in your condition after starting Abamune L, inform a doctor promptly.
Abamune L should not be taken in conjunction with other medications that contain Lamivudine or Abacavir. Patients with the HLA-B*5701 allele are at an increased risk of hypersensitive reactions to Abacavir, which can be fatal; hence, testing for this allele is recommended, even for those who have tolerated other Abacavir products before. If signs of hepatotoxicity or lactic acidosis occur, Abamune L usage must be discontinued. Patients on interferon alfa should have regular checks for liver function and toxicity. It is unsafe to use Abamune L if your creatinine clearance is below 50 ml/min.
Ethanol may impair the kidneys' ability to eliminate Abacavir. Zalcitabine should not be used alongside Abamune L, as they inhibit each other.
Animal studies during pregnancy have indicated that Abamune L may increase the risk of birth defects. Pregnant women should only take Abamune L if the potential advantages outweigh the risks and there are no alternatives available. HIV-positive mothers are advised not to breastfeed due to the risk of postnatal transmission.
The effects of an overdose of Abamune L are currently unknown. Do not exceed the recommended dosage.